



January 26, 2017

## **Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017**

ATLANTA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, February 2, 2017 at 4:30 p.m. ET to review the Company's financial results for the three month period ended December 31, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.

In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 60561525. The live webcast can be accessed under the Investors section of the Company's website at [www.aviragentherapeutics.com](http://www.aviragentherapeutics.com).

### **About Aviragen Therapeutics, Inc.**

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has four Phase 2 clinical programs: vapendavir, an oral treatment for rhinovirus (RV) upper respiratory infections in moderate-to-severe asthmatics; vapendavir is also being evaluated for the treatment of RV infections in hematopoietic stem cell transplant patients; BTA585, an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, a topical antiviral treatment for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit [www.aviragentherapeutics.com](http://www.aviragentherapeutics.com).

Contacts:

Mark Colonnese

Executive Vice President and Chief Financial Officer

Aviragen Therapeutics, Inc.

(678) 221-3381

[mcolonnese@aviragentherapeutics.com](mailto:mcolonnese@aviragentherapeutics.com)

Beth DelGiaccio

Stern Investor Relations, Inc.

(212) 362-1200

[beth@sternir.com](mailto:beth@sternir.com)

 Primary Logo

Source: Aviragen Therapeutics, Inc.

News Provided by Acquire Media